相关临床试验
1
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
1
100.0%
暂无批准数据
- A retrospective study of 154 patients with uncontrolled severe asthma demonstrated significant improvements in asthma control, lung function, and reduced exacerbations across four monoclonal antibodies after 12 months of treatment. - All four biologics (benralizumab, mepolizumab, omalizumab, and reslizumab) showed comparable effectiveness with median ACT scores increasing by six points and FEV₁ improving by 7%. - The study revealed high treatment adherence at 95% and median persistence of 2.0 years, though 42% of patients discontinued therapy primarily due to insufficient clinical response or drug supply issues. - Benralizumab and reslizumab demonstrated the greatest reductions in blood eosinophil counts, with near-complete depletion observed in treated patients.
- The combination of BO-112 and pembrolizumab achieved a 25% overall response rate in patients with advanced melanoma resistant to anti-PD-1 therapies in the phase 2 SPOTLIGHT203 trial. - Responses were observed across BRAF-mutated and wild-type melanoma, including mucosal histology and secondary anti-PD-1 resistance cases, though patients with acral melanoma showed no clinical benefit. - The treatment demonstrated manageable safety with 83% of patients experiencing treatment-related adverse events, but only 5% had grade 3 or 4 events. - The median progression-free survival was 3.8 months overall, with significantly better outcomes in patients without acral disease or very high lactate dehydrogenase levels.
